Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness

Meritxell Sabidó, Thilo Hohenberger, Guido Grassi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The study objective was to compare the long-term incidence and risk of mortality and cardiovascular outcomes in patients with hypertension initiating bisoprolol, other β-blockers or other antihypertensive therapies. Cohort analysis using UK Clinical Practice Research Datalink (CPRD). Adult patients with first diagnosis of hypertension recorded between 2000 and 2014, with ≥365 days of registration to first event and initiating monotherapies of bisoprolol, other β-blockers or drugs other than β-blockers within 6 months of diagnosis were included. Incidence rates (IR) for each treatment cohort were compared using adjusted hazard ratio (HR) and 95% confidence intervals (CI) obtained from Cox regression analyses. Of 100,066 patients included, 539 were prescribed bisoprolol, 3701 other β-blockers, and 95,826 drugs other than β blockers. Patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (HR for <15 years 0.34; 95% CI 0.18-0.67) versus other β blockers, and from 5 to <15 years (HR for <15 years 0.52; 95% CI 0.27-1.00) versus drugs other than β blockers. Over time, the risk of arrhythmia was higher in the bisoprolol cohort versus other β blockers, and risks of arrhythmia and angina were higher versus drugs other than β blockers. No differences in the risk of embolism, stroke, and myocardial infarction (MI) were found between cohorts. Over time, mortality and cardiovascular outcome IRs decreased in each cohort. In conclusion, bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other β blockers, and from 5 years versus drugs other than β blockers, providing long-term evidence supporting the use of bisoprolol in patients with hypertension in primary care.

Original languageEnglish
JournalPharmacological Research
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Bisoprolol
Pharmacology
Hypertension
Pharmaceutical Preparations
Confidence Intervals
Cardiac Arrhythmias
Survival
Mortality
Incidence
Embolism
Antihypertensive Agents
Primary Health Care
Cohort Studies
Therapeutics
Stroke
Myocardial Infarction
Regression Analysis

Keywords

  • Adrenergic
  • Adrenergic beta-antagonists
  • Antihypertensive drug
  • Beta-blocker
  • Bisoprolol
  • Cardiovascular risk
  • Cohort analysis
  • Hypertension
  • Mortality

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological intervention in hypertension using beta-blockers : Real-world evidence for long-term effectiveness. / Sabidó, Meritxell; Hohenberger, Thilo; Grassi, Guido.

In: Pharmacological Research, 01.01.2018.

Research output: Contribution to journalArticle

@article{3cef1774bae04bd095d19f95a79ff8cb,
title = "Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness",
abstract = "The study objective was to compare the long-term incidence and risk of mortality and cardiovascular outcomes in patients with hypertension initiating bisoprolol, other β-blockers or other antihypertensive therapies. Cohort analysis using UK Clinical Practice Research Datalink (CPRD). Adult patients with first diagnosis of hypertension recorded between 2000 and 2014, with ≥365 days of registration to first event and initiating monotherapies of bisoprolol, other β-blockers or drugs other than β-blockers within 6 months of diagnosis were included. Incidence rates (IR) for each treatment cohort were compared using adjusted hazard ratio (HR) and 95{\%} confidence intervals (CI) obtained from Cox regression analyses. Of 100,066 patients included, 539 were prescribed bisoprolol, 3701 other β-blockers, and 95,826 drugs other than β blockers. Patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (HR for <15 years 0.34; 95{\%} CI 0.18-0.67) versus other β blockers, and from 5 to <15 years (HR for <15 years 0.52; 95{\%} CI 0.27-1.00) versus drugs other than β blockers. Over time, the risk of arrhythmia was higher in the bisoprolol cohort versus other β blockers, and risks of arrhythmia and angina were higher versus drugs other than β blockers. No differences in the risk of embolism, stroke, and myocardial infarction (MI) were found between cohorts. Over time, mortality and cardiovascular outcome IRs decreased in each cohort. In conclusion, bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other β blockers, and from 5 years versus drugs other than β blockers, providing long-term evidence supporting the use of bisoprolol in patients with hypertension in primary care.",
keywords = "Adrenergic, Adrenergic beta-antagonists, Antihypertensive drug, Beta-blocker, Bisoprolol, Cardiovascular risk, Cohort analysis, Hypertension, Mortality",
author = "Meritxell Sabid{\'o} and Thilo Hohenberger and Guido Grassi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.phrs.2018.01.010",
language = "English",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Pharmacological intervention in hypertension using beta-blockers

T2 - Real-world evidence for long-term effectiveness

AU - Sabidó, Meritxell

AU - Hohenberger, Thilo

AU - Grassi, Guido

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The study objective was to compare the long-term incidence and risk of mortality and cardiovascular outcomes in patients with hypertension initiating bisoprolol, other β-blockers or other antihypertensive therapies. Cohort analysis using UK Clinical Practice Research Datalink (CPRD). Adult patients with first diagnosis of hypertension recorded between 2000 and 2014, with ≥365 days of registration to first event and initiating monotherapies of bisoprolol, other β-blockers or drugs other than β-blockers within 6 months of diagnosis were included. Incidence rates (IR) for each treatment cohort were compared using adjusted hazard ratio (HR) and 95% confidence intervals (CI) obtained from Cox regression analyses. Of 100,066 patients included, 539 were prescribed bisoprolol, 3701 other β-blockers, and 95,826 drugs other than β blockers. Patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (HR for <15 years 0.34; 95% CI 0.18-0.67) versus other β blockers, and from 5 to <15 years (HR for <15 years 0.52; 95% CI 0.27-1.00) versus drugs other than β blockers. Over time, the risk of arrhythmia was higher in the bisoprolol cohort versus other β blockers, and risks of arrhythmia and angina were higher versus drugs other than β blockers. No differences in the risk of embolism, stroke, and myocardial infarction (MI) were found between cohorts. Over time, mortality and cardiovascular outcome IRs decreased in each cohort. In conclusion, bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other β blockers, and from 5 years versus drugs other than β blockers, providing long-term evidence supporting the use of bisoprolol in patients with hypertension in primary care.

AB - The study objective was to compare the long-term incidence and risk of mortality and cardiovascular outcomes in patients with hypertension initiating bisoprolol, other β-blockers or other antihypertensive therapies. Cohort analysis using UK Clinical Practice Research Datalink (CPRD). Adult patients with first diagnosis of hypertension recorded between 2000 and 2014, with ≥365 days of registration to first event and initiating monotherapies of bisoprolol, other β-blockers or drugs other than β-blockers within 6 months of diagnosis were included. Incidence rates (IR) for each treatment cohort were compared using adjusted hazard ratio (HR) and 95% confidence intervals (CI) obtained from Cox regression analyses. Of 100,066 patients included, 539 were prescribed bisoprolol, 3701 other β-blockers, and 95,826 drugs other than β blockers. Patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (HR for <15 years 0.34; 95% CI 0.18-0.67) versus other β blockers, and from 5 to <15 years (HR for <15 years 0.52; 95% CI 0.27-1.00) versus drugs other than β blockers. Over time, the risk of arrhythmia was higher in the bisoprolol cohort versus other β blockers, and risks of arrhythmia and angina were higher versus drugs other than β blockers. No differences in the risk of embolism, stroke, and myocardial infarction (MI) were found between cohorts. Over time, mortality and cardiovascular outcome IRs decreased in each cohort. In conclusion, bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other β blockers, and from 5 years versus drugs other than β blockers, providing long-term evidence supporting the use of bisoprolol in patients with hypertension in primary care.

KW - Adrenergic

KW - Adrenergic beta-antagonists

KW - Antihypertensive drug

KW - Beta-blocker

KW - Bisoprolol

KW - Cardiovascular risk

KW - Cohort analysis

KW - Hypertension

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85041591981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041591981&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2018.01.010

DO - 10.1016/j.phrs.2018.01.010

M3 - Article

AN - SCOPUS:85041591981

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -